Elizabeth Olson Hexner, M.D., M.S.T.R.
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania - Rhoads 7 Liquid Tumor Service
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215.614.1847
Fax: (215) 615-5888
Fax: (215) 615-5888
Education:
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
Post-Graduate Training
Intern, Department of Medicine, Columbia Presbyterian Hospital, 1999-2000.
Resident, Department of Medicine, Columbia Presbyterian Hospital, 2000-2002.
Fellow, Hematology/Oncology, University of Pennsylvania, 2002-2005.
Intern, Department of Medicine, Columbia Presbyterian Hospital, 1999-2000.
Resident, Department of Medicine, Columbia Presbyterian Hospital, 2000-2002.
Fellow, Hematology/Oncology, University of Pennsylvania, 2002-2005.
Certifications
American Board of Internal Medicine (Internal Medicine), 2002.
American Board of Internal Medicine (Medical Oncology), 2005.
American Board of Internal Medicine (Hematology), 2005.
Permanent linkAmerican Board of Internal Medicine (Internal Medicine), 2002.
American Board of Internal Medicine (Medical Oncology), 2005.
American Board of Internal Medicine (Hematology), 2005.
Description of Research Expertise
Myeloproliferative DisordersUmbilical Cord Blood Transplantation
Description of Clinical Expertise
Myeloproliferative NeoplasmsMyelodysplastic Syndromes
Acute leukemia
Selected Publications
Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, Clementi R, Bensen-Kennedy D, and Moliterno A.: Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with the JAK2-V617F mutation. Br J Haematol 2013 (accepted).Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., Dipersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V., Kantarjian, H. M.: Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013.
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Jr., Arcasoy, M. O., Hexner, E., Lyons, R. M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V., Kantarjian, H. M.: The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161(4): 508-16, 2013.
Mesa, R. A., Kiladjian, J. J., Verstovsek, S., Al-Ali, H. K., Gotlib, J. R., Gisslinger, H., Levy, R. S., Siulnik, A., Gupta, V., Khan, M., Dipersio, J. F., McQuitty, M., Catalano, J. V., Hunter, D. S., Knoops, L., Deininger, M., Cervantes, F., Miller, C., Vannucchi, A. M., Silver, R. T., Barbui, T., Talpaz, M., Barosi, G., Winton, E. F., Mendeson, E., Harvey, J. H., Arcasoy, M. O., Hexner, E., Lyons, R. M., Paquette, R., Raza, A., Sun, W., Sandor, V., Kantarjian, H. M., Harrison, C.: Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 2013.
Landsburg, D. J., Stadtmauer, E., Loren, A., Goldstein, S., Frey, N., Nasta, S. D., Porter, D. L., Tsai, D. E., Perl, A. E., Hexner, E. O., Luger, S.: Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens. Am J Hematol 88(8): 657-60, 2013.
Kumar, A. J., Hexner, E. O., Frey, N. V., Luger, S. M., Loren, A. W., Reshef, R., Boyer, J., Smith, J., Stadtmauer, E. A., Levine, B. L., June, C. H., Porter, D. L., Goldstein, S. C.: Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biol Blood Marrow Transplant 19(7): 1094-101, 2013.
Lin, X., Rice, K. L., Buzzai, M., Hexner, E., Costa, F. F., Kilpivaara, O., Mullally, A., Soares, M. B., Ebert, B. L., Levine, R., Licht, J. D.: miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia 27: 344 - 52, 2013.
Kalota, A., Jeschke, G. R., Carroll, M., Hexner, E. O.: Intrinsic resistance to JAK2 inhibition in myelofibrosis. Clin Cancer Res 2013.
Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL. : High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant. 47(10): 1332-7, Oct 2012.
Verstovsek, S., Mesa, R. A. Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Jr., Arcasoy, M. O., Hexner, E., Lyons, R. M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I. L., Sun, W., Sandor, V., Kantarjian, H. M.: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9): 799-807, March 2012.
